Optical Cervical Cancer Detection Devices Draft Guidance Reissued May 24
This article was originally published in The Gray Sheet
Executive Summary
Test data that both demonstrates the biocompatibility of materials used at the device/cervix interface and characterizes the foreseeable hazards posed by optical radiation or thermal effects must be provided by companies seeking to market devices for the optical detection of cervical cancer and its precursors, FDA says in a draft guidance released May 24 on the agency's website.
You may also be interested in...
Electro-optical sensors guidance document
Comments on FDA's "Draft Guidance for Industry on the Electro-Optical Sensors for the In Vivo Detection of Cervical Cancer and its Precursors" are due Nov. 23, the agency says in an Aug. 25 Federal Register notice. FDA released the guidance in May (1"The Gray Sheet" May 31, p. 7)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.